Amundi Sells 30,673 Shares of Neurocrine Biosciences, Inc. $NBIX

Amundi lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 11.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 231,187 shares of the company's stock after selling 30,673 shares during the period. Amundi owned 0.23% of Neurocrine Biosciences worth $23,785,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NBIX. Dodge & Cox lifted its position in shares of Neurocrine Biosciences by 83.5% during the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company's stock valued at $612,129,000 after buying an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Neurocrine Biosciences by 44.0% during the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company's stock valued at $232,037,000 after buying an additional 640,556 shares during the last quarter. Orbimed Advisors LLC lifted its position in shares of Neurocrine Biosciences by 210.4% during the 4th quarter. Orbimed Advisors LLC now owns 938,120 shares of the company's stock valued at $128,053,000 after buying an additional 635,900 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Neurocrine Biosciences by 1,405.2% during the 1st quarter. Assenagon Asset Management S.A. now owns 393,455 shares of the company's stock valued at $43,516,000 after buying an additional 367,315 shares during the last quarter. Finally, Braidwell LP lifted its position in shares of Neurocrine Biosciences by 32.2% during the 1st quarter. Braidwell LP now owns 1,191,925 shares of the company's stock valued at $131,827,000 after buying an additional 290,135 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded down $1.73 during trading on Friday, reaching $141.87. The company's stock had a trading volume of 485,690 shares, compared to its average volume of 702,053. The stock has a market capitalization of $14.07 billion, a PE ratio of 41.97, a P/E/G ratio of 1.03 and a beta of 0.28. The firm has a fifty day moving average of $134.13 and a 200 day moving average of $121.18. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $154.61.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.08. The business had revenue of $687.50 million for the quarter, compared to analyst estimates of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company's quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.63 EPS. Research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Piper Sandler increased their price objective on Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an "overweight" rating in a report on Thursday, July 31st. Truist Financial assumed coverage on Neurocrine Biosciences in a report on Monday, July 21st. They set a "buy" rating and a $163.00 price objective on the stock. Wall Street Zen raised Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Royal Bank Of Canada increased their price objective on Neurocrine Biosciences from $144.00 to $149.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Finally, The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a report on Thursday, July 10th. They set a "buy" rating and a $182.00 price objective on the stock. Eighteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $160.00.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 457 shares of the stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the transaction, the insider directly owned 4,730 shares in the company, valued at approximately $638,550. This represents a 8.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jude Onyia sold 59,819 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the transaction, the insider owned 18,289 shares in the company, valued at $2,385,982.94. This trade represents a 76.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 186,960 shares of company stock worth $23,955,553 in the last ninety days. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.